News and Events

Biotechnology Training Program 2022 Opening Ceremony

news-primary-img

THE OPENING CEREMONY OF BIOTECHNOLOGY TRAINING PROGRAM 2022: KGM TOGETHER WITH i3L SUPPORTING BIOTECHNOLOGY ENGINEER FUTURE LEADER

Kalbio Global Medika (KGM) officially opened the 2022 Biotechnology Training Program on July 1st, 2022, which will collaborate with the Indonesia International Institute for Life-Sciences (i3L) throughout the process for the next 6 months. This year's Biotechnology Training Program is the third implementation since the program was first implemented in 2015. The Opening Ceremony, which was held at the Indonesia International Institute for Life-Sciences, was attended by the management board of Kalbe and Kalbio Global Medika, participants of the 2022 Biotechnology Training Program, and Kalbio Global Medika's personnel as a form of support to make the program a success.

The Biotechnology Training Program is an intensive training program packaged as learning assignments for selected employees at Kalbio Global Medika to increase their knowledge and skills in the fields of Science and Biotechnology in order to produce future leaders who are competent and qualified in their fields.

Later on, the "Graduates" of the Biotechnology Training Program are expected to become the Successors for the current Leaders at Kalbio Global Medika and are hoped to bring new innovations based on the knowledge they have gained during the training, so that they can make a real contribution to advance a better life, especially in the health sector.

news-detail-img news-detail-img


KGM at a Glance

Kalbio Global Medika (KGM) is one of the first and the pioneer of biopharmaceuticals in Indonesia, established in 2014 and inaugurated officially in 2018 by the President of the Republic of Indonesia, Ir. Joko Widodo. KGM is part of the Kalbe Group, a subsidiary of PT Kalbe Genexine Biologics (KGbio), which is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside US/Canada, Western Europe, and China. KGM is an Innovative CDMO, equipped with CMC and scale-up capabilities plugged into Boston biotech ecosystem and state-of-the-art facility to enhance efficiency and productivity. With API manufacturing, formulation, fill and finish capabilities of biosimilar and novel biologics, averaging 10 million units of syringes, cartridges, and vials, KGM supplies local and international markets.

Kalbe at a Glance

PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle a portfolio of dependable and various brands: the prescription pharmaceutical division, the health products division that handles over-the-counter drugs, multivitamins, and ready-to-serve supplemental drinks, the nutritions division, and the distribution & logistics division.

Kalbe has also developed a B2B-based digital services ecosystem for the society: EMOS and KlikDokter, a B2C service. EMOS is an order management application system that helps distribution channels perform their stock or supply chain management actions. KlikDokter is a digital platform for healthcare services focusing on telemedicine, which provides health consultation and products that are needed by the society.

Kalbe now has more than 40 subsidiaries and 15 international-standard production facilities, supported by around 16,000 employees in 76 branches throughout Indonesia. Kalbe’s shares have been listed in Indonesia Stock Exchange/Bursa Efek Indonesia (IDX:KLBF) since 1991.